We are live on ! Find out more
APLS

Apellis Pharmaceuticals
APLS

Delisted

APLS was delisted on the 13th of May, 2026.

Back to rankings

46 hedge funds and large institutions have $340M invested in Apellis Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 46 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

31.29% more ownership

Funds ownership: 0% → 31.29% (+31%)

Holders
46
Holders Change
+46
Holders Change %
–
% of All Funds
1.04%
Holding in Top 10
4
Holding in Top 10 Change
+4
Holding in Top 10 Change %
% of All Funds
0.09%
New
46
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CAM
Cormorant Asset Management
Massachusetts
+$55.5M
2
SAM
Sectoral Asset Management
Quebec, Canada
+$25.8M
3
VC
Vivo Capital
California
+$21.5M
4
HIM
Hillhouse Investment Management
Cayman Islands
+$21M
5
EC
EcoR1 Capital
California
+$16.8M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
26
Morgan Stanley
New York
$410K +$278K +18,908 New
ECM
27
Endurant Capital Management
California
$382K +$259K +17,600 New
California State Teachers Retirement System (CalSTRS)
28
California State Teachers Retirement System (CalSTRS)
California
$370K +$251K +17,066 New
TCIM
29
TIAA CREF Investment Management
New York
$343K +$233K +15,829 New
QSS
30
Quantitative Systematic Strategies
Florida
$317K +$215K +14,586 New
TA
31
Teachers Advisors
New York
$270K +$183K +12,435 New
Manulife (Manufacturers Life Insurance)
32
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$186K +$126K +8,551 New
AIG
33
American International Group
New York
$158K +$107K +7,292 New
UBS Group
34
UBS Group
Switzerland
$85K +$57.5K +3,903 New
SO
35
STRS Ohio
Ohio
$67K +$45.6K +3,100 New
JP Morgan Chase
36
JP Morgan Chase
New York
$51K +$34.4K +2,335 New
BNP Paribas Financial Markets
37
BNP Paribas Financial Markets
France
$48.8K +$33.1K +2,250 New
Legal & General Group
38
Legal & General Group
United Kingdom
$41K +$27.7K +1,882 New
Barclays
39
Barclays
United Kingdom
$37K +$25.3K +1,717 New
Parallax Volatility Advisers
40
Parallax Volatility Advisers
California
$36K +$24.7K +1,680 New
Wells Fargo
41
Wells Fargo
California
$35K +$23.5K +1,596 New
Bank of America
42
Bank of America
North Carolina
$30K +$20.3K +1,380 New
Citigroup
43
Citigroup
New York
$26K +$18K +1,220 New
AIP
44
Ameritas Investment Partners
Nebraska
$20K +$13.5K +920 New
CCA
45
Catalyst Capital Advisors
New York
$7K +$5.08K +345 New
Royal Bank of Canada
46
Royal Bank of Canada
Ontario, Canada
$2K +$1.44K +98 New
1
2

APLS Hedge Fund Activity: Q4 2017 in Review

46 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Apellis Pharmaceuticals (APLS) for Q4 2017, worth a combined $340M.

Buyers outnumbered sellers: 46 funds opened new APLS positions and 0 closed out — a net gain of 46 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Cormorant Asset Management, opening a new position worth an estimated $55.5M.

  • 46 institutional investors held Apellis Pharmaceuticals (APLS) as of Q4 2017, up from 0 in Q3 2017.
  • Funds reported $340M of Apellis Pharmaceuticals stock for Q4 2017.
  • 46 funds opened new Apellis Pharmaceuticals positions in Q4 2017 and 0 closed out, a net change of +46 holders.
  • The largest Apellis Pharmaceuticals buyer in Q4 2017 was Cormorant Asset Management, an estimated $55.5M added.

Based on aggregated 13F filings for Q4 2017.